286 related articles for article (PubMed ID: 32697072)
1. Structural Insights into PROTAC-Mediated Degradation of Bcl-xL.
Chung CW; Dai H; Fernandez E; Tinworth CP; Churcher I; Cryan J; Denyer J; Harling JD; Konopacka A; Queisser MA; Tame CJ; Watt G; Jiang F; Qian D; Benowitz AB
ACS Chem Biol; 2020 Sep; 15(9):2316-2323. PubMed ID: 32697072
[TBL] [Abstract][Full Text] [Related]
2. Development of a BCL-xL and BCL-2 dual degrader with improved anti-leukemic activity.
Lv D; Pal P; Liu X; Jia Y; Thummuri D; Zhang P; Hu W; Pei J; Zhang Q; Zhou S; Khan S; Zhang X; Hua N; Yang Q; Arango S; Zhang W; Nayak D; Olsen SK; Weintraub ST; Hromas R; Konopleva M; Yuan Y; Zheng G; Zhou D
Nat Commun; 2021 Nov; 12(1):6896. PubMed ID: 34824248
[TBL] [Abstract][Full Text] [Related]
3. Discovery of a Novel BCL-X
Pal P; Thummuri D; Lv D; Liu X; Zhang P; Hu W; Poddar SK; Hua N; Khan S; Yuan Y; Zhang X; Zhou D; Zheng G
J Med Chem; 2021 Oct; 64(19):14230-14246. PubMed ID: 34533954
[TBL] [Abstract][Full Text] [Related]
4. Discovery of IAP-recruiting BCL-X
Zhang X; He Y; Zhang P; Budamagunta V; Lv D; Thummuri D; Yang Y; Pei J; Yuan Y; Zhou D; Zheng G
Eur J Med Chem; 2020 Aug; 199():112397. PubMed ID: 32388279
[TBL] [Abstract][Full Text] [Related]
5. Utilizing PROTAC technology to address the on-target platelet toxicity associated with inhibition of BCL-X
Zhang X; Thummuri D; He Y; Liu X; Zhang P; Zhou D; Zheng G
Chem Commun (Camb); 2019 Dec; 55(98):14765-14768. PubMed ID: 31754664
[TBL] [Abstract][Full Text] [Related]
6. Discovery of PROTAC BCL-X
Zhang X; Thummuri D; Liu X; Hu W; Zhang P; Khan S; Yuan Y; Zhou D; Zheng G
Eur J Med Chem; 2020 Apr; 192():112186. PubMed ID: 32145645
[TBL] [Abstract][Full Text] [Related]
7. A selective BCL-X
Khan S; Zhang X; Lv D; Zhang Q; He Y; Zhang P; Liu X; Thummuri D; Yuan Y; Wiegand JS; Pei J; Zhang W; Sharma A; McCurdy CR; Kuruvilla VM; Baran N; Ferrando AA; Kim YM; Rogojina A; Houghton PJ; Huang G; Hromas R; Konopleva M; Zheng G; Zhou D
Nat Med; 2019 Dec; 25(12):1938-1947. PubMed ID: 31792461
[TBL] [Abstract][Full Text] [Related]
8. Development and crystal structures of a potent second-generation dual degrader of BCL-2 and BCL-xL.
Nayak D; Lv D; Yuan Y; Zhang P; Hu W; Nayak A; Ruben EA; Lv Z; Sung P; Hromas R; Zheng G; Zhou D; Olsen SK
Nat Commun; 2024 Mar; 15(1):2743. PubMed ID: 38548768
[TBL] [Abstract][Full Text] [Related]
9. DT2216-a Bcl-xL-specific degrader is highly active against Bcl-xL-dependent T cell lymphomas.
He Y; Koch R; Budamagunta V; Zhang P; Zhang X; Khan S; Thummuri D; Ortiz YT; Zhang X; Lv D; Wiegand JS; Li W; Palmer AC; Zheng G; Weinstock DM; Zhou D
J Hematol Oncol; 2020 Jul; 13(1):95. PubMed ID: 32677976
[TBL] [Abstract][Full Text] [Related]
10. Strategies to Reduce the On-Target Platelet Toxicity of Bcl-x
Negi A; Voisin-Chiret AS
Chembiochem; 2022 Jun; 23(12):e202100689. PubMed ID: 35263486
[TBL] [Abstract][Full Text] [Related]
11. Discovery of small molecule ligands for the von Hippel-Lindau (VHL) E3 ligase and their use as inhibitors and PROTAC degraders.
Diehl CJ; Ciulli A
Chem Soc Rev; 2022 Oct; 51(19):8216-8257. PubMed ID: 35983982
[TBL] [Abstract][Full Text] [Related]
12. Differential PROTAC substrate specificity dictated by orientation of recruited E3 ligase.
Smith BE; Wang SL; Jaime-Figueroa S; Harbin A; Wang J; Hamman BD; Crews CM
Nat Commun; 2019 Jan; 10(1):131. PubMed ID: 30631068
[TBL] [Abstract][Full Text] [Related]
13. Structural basis of PROTAC cooperative recognition for selective protein degradation.
Gadd MS; Testa A; Lucas X; Chan KH; Chen W; Lamont DJ; Zengerle M; Ciulli A
Nat Chem Biol; 2017 May; 13(5):514-521. PubMed ID: 28288108
[TBL] [Abstract][Full Text] [Related]
14. The PROTAC selectively degrading Bcl-x
Zhang S; Chen Y; Xu Z; Yang J; Sun R; Wang J; Sun Y; Jiang B; Yang X; Tan W
Theranostics; 2022; 12(17):7476-7490. PubMed ID: 36438482
[No Abstract] [Full Text] [Related]
15. Using proteolysis-targeting chimera technology to reduce navitoclax platelet toxicity and improve its senolytic activity.
He Y; Zhang X; Chang J; Kim HN; Zhang P; Wang Y; Khan S; Liu X; Zhang X; Lv D; Song L; Li W; Thummuri D; Yuan Y; Wiegand JS; Ortiz YT; Budamagunta V; Elisseeff JH; Campisi J; Almeida M; Zheng G; Zhou D
Nat Commun; 2020 Apr; 11(1):1996. PubMed ID: 32332723
[TBL] [Abstract][Full Text] [Related]
16. Iterative Design and Optimization of Initially Inactive Proteolysis Targeting Chimeras (PROTACs) Identify VZ185 as a Potent, Fast, and Selective von Hippel-Lindau (VHL) Based Dual Degrader Probe of BRD9 and BRD7.
Zoppi V; Hughes SJ; Maniaci C; Testa A; Gmaschitz T; Wieshofer C; Koegl M; Riching KM; Daniels DL; Spallarossa A; Ciulli A
J Med Chem; 2019 Jan; 62(2):699-726. PubMed ID: 30540463
[TBL] [Abstract][Full Text] [Related]
17. PROTACs are effective in addressing the platelet toxicity associated with BCL-X
Zhang P; Zhang X; Liu X; Khan S; Zhou D; Zheng G
Explor Target Antitumor Ther; 2020; 1(4):259-272. PubMed ID: 34296214
[TBL] [Abstract][Full Text] [Related]
18. Co-targeting BCL-XL and BCL-2 by PROTAC 753B eliminates leukemia cells and enhances efficacy of chemotherapy by targeting senescent cells.
Jia Y; Han L; Ramage CL; Wang Z; Weng CC; Yang L; Colla S; Ma H; Zhang W; Andreeff M; Daver N; Jain N; Pemmaraju N; Bhalla K; Mustjoki S; Zhang P; Zheng G; Zhou D; Zhang Q; Konopleva M
Haematologica; 2023 Oct; 108(10):2626-2638. PubMed ID: 37078252
[TBL] [Abstract][Full Text] [Related]
19. PROTAC-mediated crosstalk between E3 ligases.
Steinebach C; Kehm H; Lindner S; Vu LP; Köpff S; López Mármol Á; Weiler C; Wagner KG; Reichenzeller M; Krönke J; Gütschow M
Chem Commun (Camb); 2019 Feb; 55(12):1821-1824. PubMed ID: 30672516
[TBL] [Abstract][Full Text] [Related]
20. Discovery of Highly Potent and Efficient PROTAC Degraders of Androgen Receptor (AR) by Employing Weak Binding Affinity VHL E3 Ligase Ligands.
Han X; Zhao L; Xiang W; Qin C; Miao B; Xu T; Wang M; Yang CY; Chinnaswamy K; Stuckey J; Wang S
J Med Chem; 2019 Dec; 62(24):11218-11231. PubMed ID: 31804827
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
